The DOI matches its Crossref record.
Metabolic syndrome as a prognostic factor for breast cancer recurrences
Abstract
Several studies have shown that hormonal, metabolic and inflammatory mechanisms may affect breast cancer progression. We tested the prognostic value of metabolic syndrome in 110 postmenopausal breast cancer patients, who participated in a 1‐year dietary intervention study. The risk of adverse events after 5.5 years of follow‐up was examined by Cox' proportional hazard modelling, adjusting for hormone receptor status, stage at diagnosis and serum testosterone level, which were shown to significantly affect prognosis. The adjusted hazard ratio of recurrence for the presence of metabolic syndrome at baseline was 3.0 (95% CI 1.2–7.1). Combining metabolic syndrome and serum testosterone, the adjusted hazard ratio of recurrence among women with metabolic syndrome and testosterone levels higher than 0.40 ng/ml (median value) was 6.7 (95% CI 2.3–19.8) compared with that among women without metabolic syndrome and testosterone levels ≤0.40 ng/ml. The results suggest that metabolic syndrome may be an important prognostic factor for breast cancer. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Role of Phenolic Compounds in Human Disease: Current Knowledge and Future Prospects
Rahman, M. M., Rahaman, M. S., Islam, M. R., Rahman, F., Mithi, F. M., Alqahtani, T., Almikhlafi, M. A., Alghamdi, S. Q., Alruwaili, A. S., Hossain, M. S., et al. (2021) · Molecules · doi:10.3390/molecules27010233 · Cited by 852
Cowey, S., & Hardy, R. W. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.051090 · Cited by 431
Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment and Recurrence
De Cicco, P., Catani, M. V., Gasperi, V., Sibilano, M., Quaglietta, M., & Savini, I. (2019) · Nutrients · doi:10.3390/nu11071514 · Cited by 403
Dieli-Conwright, C. M., Courneya, K. S., Demark-Wahnefried, W., Sami, N., Lee, K., Buchanan, T. A., Spicer, D. V., Tripathy, D., Bernstein, L., & Mortimer, J. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7526 · Cited by 366
Metformin in cancer: translational challenges
Dowling, R. J. O., Niraula, S., Stambolic, V., & Goodwin, P. J. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0007 · Cited by 355
Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer
Goodwin, P. J., Ennis, M., Pritchard, K. I., Koo, J., & Hood, N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0725 · Cited by 339
Brand, J. S., van der Tweel, I., Grobbee, D. E., Emmelot-Vonk, M. H., & van der Schouw, Y. T. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyq158 · Cited by 334
Metformin: Multi-faceted protection against cancer
Del Barco, S., Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., & Menendez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 302
Associations of Insulin Resistance and Adiponectin With Mortality in Women With Breast Cancer
Duggan, C., Irwin, M. L., Xiao, L., Henderson, K. D., Smith, A. W., Baumgartner, R. N., Baumgartner, K. B., Bernstein, L., Ballard-Barbash, R., & McTiernan, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4473 · Cited by 294
The Role of Obesity in Cancer Survival and Recurrence
Demark-Wahnefried, W., Platz, E. A., Ligibel, J. A., Blair, C. K., Courneya, K. S., Meyerhardt, J. A., Ganz, P. A., Rock, C. L., Schmitz, K. H., Wadden, T., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0485 · Cited by 290
Ligibel, J. A., Campbell, N., Partridge, A., Chen, W. Y., Salinardi, T., Chen, H., Adloff, K., Keshaviah, A., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7357 · Cited by 289
Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer
Vona‐Davis, L., Howard‐McNatt, M., & Rose, D. P. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00396.x · Cited by 263
Resistance Exercise Training as a Primary Countermeasure to Age-Related Chronic Disease
Mcleod, J. C., Stokes, T., & Phillips, S. M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00645 · Cited by 254
Wolpin, B. M., Meyerhardt, J. A., Chan, A. T., Ng, K., Chan, J. A., Wu, K., Pollak, M. N., Giovannucci, E. L., & Fuchs, C. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9945 · Cited by 231
Goodwin, P. J., Segal, R. J., Vallis, M., Ligibel, J. A., Pond, G. R., Robidoux, A., Blackburn, G. L., Findlay, B., Gralow, J. R., Mukherjee, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1517 · Cited by 197
The impact of diabetes on survival following breast cancer
Lipscombe, L. L., Goodwin, P. J., Zinman, B., McLaughlin, J. R., & Hux, J. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9654-0 · Cited by 176
Glucose Promotes Breast Cancer Aggression and Reduces Metformin Efficacy
Wahdan-Alaswad, R., Fan, Z., Edgerton, S. M., Liu, B., Deng, X.-S., Arnadottir, S. S., Richer, J. K., Anderson, S. M., & Thor, A. D. (2013) · Cell Cycle · doi:10.4161/cc.26641 · Cited by 125
Dowling, R. J., Niraula, S., Chang, M. C., Done, S. J., Ennis, M., McCready, D. R., Leong, W. L., Escallon, J. M., Reedijk, M., Goodwin, P. J., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0540-0 · Cited by 117
Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer
Mulligan, A. M., O’Malley, F. P., Ennis, M., Fantus, I. G., & Goodwin, P. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9471-x · Cited by 96
Metadata
- Authors
- Pasanisi, P., Berrino, F., De Petris, M., Venturelli, E., Mastroianni, A., & Panico, S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2006-04-17
- Volume
- 119
- Issue
- 1
- Pages
- 236-238
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1971255955
- Cited by
- 244
- References
- 0
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.